Table 1 Demographics and Baseline Characteristics of Study Subjects
Characteristic | Evaluable subjects |
|---|---|
N = 10 | |
Age (years) | |
Median (IQR) | 22.5 (22, 40) |
Sex | |
Female | 7 (70 %) |
Male | 3 (30 %) |
Race | |
White | 5 (50 %) |
Black or African American | 3 (30 %) |
Asian | 1 (10 %) |
Multi-Racial | 1 (10 %) |
Body Mass Index (kg/m2) | |
Median (IQR) | 23.0 (21.4, 24.3) |
FEV1, Baseline (day 0) | |
Median (IQR) | 3.09 (2.78, 3.62) |
FEV1 % Predicted, Baseline (day 0) | |
Mean (SD) | 95.1 (11.6) |
PC20, Baseline (screening, mg/m2) | |
Median (IQR) | 1.79 (0.49, 3.62) |
Asthma Medications (baseline) | |
Short Acting Beta Agonist, inhaled | 9 (90 %) |
Long Acting Beta Agonist/Glucocorticoid, inhaled | 2 (20 %) |
Glucocorticoid, inhaled | 1 (10 %) |
Leukotriene-receptor antagonist | 2 (20 %) |